{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:31:35Z","timestamp":1788931895739,"version":"build-2803163510"},"reference-count":102,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arrhythm Electrophysiol Rev"],"abstract":"<jats:p>The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and  atrial cardiomyopathy.<\/jats:p>","DOI":"10.15420\/aer.2025.53","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:40:06Z","timestamp":1773150006000},"source":"Crossref","is-referenced-by-count":3,"title":["Atrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-0387","authenticated-orcid":false,"given":"Bharat K","family":"Kantharia","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-5040","authenticated-orcid":false,"given":"Lingling","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01vx35703","id-type":"ROR","asserted-by":"publisher"}],"name":"East Carolina University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit M","family":"Hulsurkar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pttbw34","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5613-6335","authenticated-orcid":false,"given":"Kaveh","family":"Karimzad","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti N","family":"Shah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Narasimhan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05dq2gs74","id-type":"ROR","asserted-by":"publisher"}],"name":"Vanderbilt University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5044-672X","authenticated-orcid":false,"given":"Xander HT","family":"Wehrens","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02pttbw34","id-type":"ROR","asserted-by":"publisher"}],"name":"Baylor College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-0824","authenticated-orcid":false,"given":"Dominik","family":"Linz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02d9ce178","id-type":"ROR","asserted-by":"publisher"}],"name":"Maastricht University Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-108X","authenticated-orcid":false,"given":"Jordi","family":"Heijman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02d9ce178","id-type":"ROR","asserted-by":"publisher"}],"name":"Maastricht University Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013; PMID:\u00a035150240.","DOI":"10.1093\/cvr\/cvac013"},{"key":"ref1","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref2","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 2022;79:1757\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011; PMID:\u00a035379504."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation 2014;129:837\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005119; PMID:\u00a024345399.","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024;37:100786. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100786; PMID:\u00a038362546.","DOI":"10.1016\/j.lanepe.2023.100786"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2023;149:e1\u2013e156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193; PMID:\u00a038033089.","DOI":"10.1161\/CIR.0000000000001207"},{"key":"ref6","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176; PMID:\u00a039210723."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"L\u00e9vy S, Steinbeck G, Santini L, et al. Management of atrial fibrillation: two decades of progress \u2013 a scientific statement from the European Cardiac Arrhythmia Society. J Interv Card Electrophysiol 2022;65:287\u2013326. https:\/\/doi.org\/10.1007\/s10840-022-01195-z; PMID:\u00a035419669.","DOI":"10.1007\/s10840-022-01195-z"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Kantharia BK. Heart failure and atrial fibrillation: is atrial fibrillation ablation in heart failure pointless or mandatory? J Cardiovasc Electrophysiol 2024;35:530\u20137. https:\/\/doi.org\/10.1111\/jce.16021; PMID:\u00a037548071.","DOI":"10.1111\/jce.16021"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kantharia BK. Cardiac arrhythmias in congestive heart failure. Expert Rev Cardiovasc Ther 2010;8:137\u201340. https:\/\/doi.org\/10.1586\/erc.09.185; PMID:\u00a020136597.","DOI":"10.1586\/erc.09.185"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme \u2013 a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003;24:442\u201363. https:\/\/doi.org\/10.1016\/S0195-668X(02)00823-0; PMID:\u00a012633546.","DOI":"10.1016\/S0195-668X(02)00823-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Rivero-Ayerza M, Scholte Op Reimer WS, Lenzen M, et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 2008;29:1618\u201324. https:\/\/doi.org\/10.1093\/eurheartj\/ehn217; PMID:\u00a018515809.","DOI":"10.1093\/eurheartj\/ehn217"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840\u20134. https:\/\/doi.org\/10.1001\/jama.1994.03510350050036; PMID:\u00a08114238.","DOI":"10.1001\/jama.1994.03510350050036"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Niiranen TJ, Schnabel RB, Schutte AE, et al. Hypertension and atrial fibrillation: a frontier review from the AF-SCREEN international collaboration. Circulation 2025;151:863\u201377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.071047; PMID:\u00a040127157.","DOI":"10.1161\/CIRCULATIONAHA.124.071047"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Zhao S, Linz D, et al. Hypertension and atrial fibrillation: insight from basic to translational science into the mechanisms and management. J Cardiovasc Electrophysiol 2025;36:2712\u20139. https:\/\/doi.org\/10.1111\/jce.16632; PMID:\u00a040051126.","DOI":"10.1111\/jce.16632"},{"key":"ref15","unstructured":"Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. J Am Coll Cardiol 2017;70:1325\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.755; PMID:\u00a028882229."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Tabary M, Wu L, et al. Diabetes and atrial fibrillation: insight from basic to translational science into the mechanisms and management. J Cardiovasc Electrophysiol 2025;36:2755\u201366. https:\/\/doi.org\/10.1111\/jce.16655; PMID:\u00a040170342.","DOI":"10.1111\/jce.16655"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sama C, Fongwen NT, Chobufo MD, et al. A systematic review and meta-analysis of the prevalence, incidence, and predictors of atrial fibrillation in cardiac sarcoidosis. Int J Cardiol 2023;391:131285. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131285; PMID:\u00a037619882.","DOI":"10.1016\/j.ijcard.2023.131285"},{"key":"ref18","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072; PMID:\u00a033825853."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Vergaro G, Aimo A, Rapezzi C, et al. Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail 2022;24:2019\u201328. https:\/\/doi.org\/10.1002\/ejhf.2650; PMID:\u00a035920110.","DOI":"10.1002\/ejhf.2650"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Skov JK, Ladefoged B, Pedersen ALD, et al. Atrial fibrillation burden, risk factors, and prognosis in wild-type transthyretin amyloidosis cardiomyopathy. Am J Cardiol 2025;254:85\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2025.06.015; PMID:\u00a040588091.","DOI":"10.1016\/j.amjcard.2025.06.015"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Hulsurkar MM, Heijman J, et al. Atrial fibrillation in transthyretin amyloid cardiac atrial cardiomyopathy: mechanisms, prevalence, and clinical implications. Am J Cardiol 2025. https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.003; PMID:\u00a040675466; epub ahead of press.","DOI":"10.1016\/j.amjcard.2025.07.003"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yun JP, Choi EK, Han KD, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol 2021;3:221\u201332. https:\/\/doi.org\/10.1016\/j.jaccao.2021.03.006; PMID:\u00a034396327.","DOI":"10.1016\/j.jaccao.2021.03.006"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Potter AS, Hulsurkar MM, Wu L, et al. Kinase inhibitors and atrial fibrillation: mechanisms of action and clinical implications. JACC Clin Electrophysiol 2023;9:591\u2013602. https:\/\/doi.org\/10.1016\/j.jacep.2022.11.034; PMID:\u00a037100538.","DOI":"10.1016\/j.jacep.2022.11.034"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Font J, Milliez P, Ouazar AB, et al. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis 2023;116:219\u201326. https:\/\/doi.org\/10.1016\/j.acvd.2023.02.005; PMID:\u00a037002156.","DOI":"10.1016\/j.acvd.2023.02.005"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Goette A, Corradi D, Dobrev D, et al. Atrial cardiomyopathy revisited \u2013 evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 2024;26:euae204. https:\/\/doi.org\/10.1093\/europace\/euae204; PMID:\u00a039077825.","DOI":"10.1093\/europace\/euae204"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Weerts J, \u021aica O, Aranyo J, et al. Atrial cardiomyopathy: from healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail 2025;27:2173\u201394. https:\/\/doi.org\/10.1002\/ejhf.3782; PMID:\u00a040763073.","DOI":"10.1002\/ejhf.3782"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.064; PMID:\u00a018294563.","DOI":"10.1016\/j.jacc.2007.09.064"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-\u03b2 signaling in fibrosis. Growth Factors 2011;29:196\u2013202. https:\/\/doi.org\/10.3109\/08977194.2011.595714; PMID:\u00a021740331.","DOI":"10.3109\/08977194.2011.595714"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Zhao F, Zhang S, Chen Y, et al. Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-\u03b21 levels in serum of patients with atrial fibrillation. BMC Cardiovasc Disord 2014;14:167. https:\/\/doi.org\/10.1186\/1471-2261-14-167; PMID:\u00a025422138.","DOI":"10.1186\/1471-2261-14-167"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Canpolat U, Oto A, Hazirolan T, et al. A prospective DE-MRI study evaluating the role of TGF-\u03b21 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy. J Cardiovasc Electrophysiol 2015;26:251\u20139. https:\/\/doi.org\/10.1111\/jce.12578; PMID:\u00a025366936.","DOI":"10.1111\/jce.12578"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012;60:2263\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2012.04.063; PMID:\u00a023194937.","DOI":"10.1016\/j.jacc.2012.04.063"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015;79:495\u2013502. https:\/\/doi.org\/10.1253\/circj.CJ-15-0138; PMID:\u00a025746525.","DOI":"10.1253\/circj.CJ-15-0138"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Korantzopoulos P, Letsas KP, Tse G, et al. Inflammation and atrial fibrillation: a comprehensive review. J Arrhythm 2018;34:394\u2013401. https:\/\/doi.org\/10.1002\/joa3.12077; PMID:\u00a030167010.","DOI":"10.1002\/joa3.12077"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Daou D, Gillette TG, Hill JA. Inflammatory mechanisms in heart failure with preserved ejection fraction. Physiology (Bethesda) 2023;38:0. https:\/\/doi.org\/10.1152\/physiol.00004.2023; PMID:\u00a037013947.","DOI":"10.1152\/physiol.00004.2023"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Pugliese NR, Pellicori P, Filidei F, et al. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res 2023;118:3536\u201355. https:\/\/doi.org\/10.1093\/cvr\/cvac133; PMID:\u00a036004819.","DOI":"10.1093\/cvr\/cvac133"},{"key":"ref36","unstructured":"Yao C, Veleva T, Scott L Jr, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation 2018;138:2227\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035202; PMID:\u00a029802206."},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Heijman J, Muna AP, Veleva T, et al. Atrial myocyte NLRP3\/CaMKII nexus forms a substrate for postoperative atrial fibrillation. Circ Res 2020;127:1036\u201355. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316710; PMID:\u00a032762493.","DOI":"10.1161\/CIRCRESAHA.120.316710"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Toldo S, Mezzaroma E, Buckley LF, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther 2022;236:108053. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108053; PMID:\u00a034906598.","DOI":"10.1016\/j.pharmthera.2021.108053"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008;1:62\u201373. https:\/\/doi.org\/10.1161\/CIRCEP.107.754564; PMID:\u00a019808395.","DOI":"10.1161\/CIRCEP.107.754564"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Voigt N, Heijman J, Trausch A, et al. Impaired Na+-dependent regulation of acetylcholine-activated inward-rectifier K+ current modulates action potential rate dependence in patients with chronic atrial fibrillation. J Mol Cell Cardiol 2013;61:142\u201352. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.03.011; PMID:\u00a023531443.","DOI":"10.1016\/j.yjmcc.2013.03.011"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Heijman J, Voigt N, Wehrens XHT, Dobrev D. Calcium dysregulation in atrial fibrillation: the role of CaMKII. Front Pharmacol 2014;5:30. https:\/\/doi.org\/10.3389\/fphar.2014.00030; PMID:\u00a024624086.","DOI":"10.3389\/fphar.2014.00030"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Heijman J, Voigt N, Ghezelbash S, et al. Calcium handling abnormalities as a target for atrial fibrillation therapeutics: how close to clinical implementation? J Cardiovasc Pharmacol 2015;66:515\u201322. https:\/\/doi.org\/10.1097\/FJC.0000000000000253; PMID:\u00a025830486.","DOI":"10.1097\/FJC.0000000000000253"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Landstrom AP, Dobrev D, Wehrens XHT. Calcium signaling and cardiac arrhythmias. Circ Res 2017;120:1969\u201393. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310083; PMID:\u00a028596175.","DOI":"10.1161\/CIRCRESAHA.117.310083"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Vest JA, Wehrens XHT, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005;111:2025\u201332. https:\/\/doi.org\/10.1161\/01.CIR.0000162461.67140.4C; PMID:\u00a015851612.","DOI":"10.1161\/01.CIR.0000162461.67140.4C"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest 2009;119:1940\u201351. https:\/\/doi.org\/10.1172\/jci37059; PMID:\u00a019603549.","DOI":"10.1172\/JCI37059"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Campbell HM, Quick AP, Abu-Taha I, et al. Loss of SPEG inhibitory phosphorylation of ryanodine receptor type-2 promotes atrial fibrillation. Circulation 2020;142:1159\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045791; PMID:\u00a032683896.","DOI":"10.1161\/CIRCULATIONAHA.120.045791"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 2012;125:2059\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.067306; PMID:\u00a022456474.","DOI":"10.1161\/CIRCULATIONAHA.111.067306"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Heijman J, Zhou X, Morotti S, et al. Enhanced Ca2+-dependent SK-channel gating and membrane trafficking in human atrial fibrillation. Circ Res 2023;132:e116\u201333. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.321858; PMID:\u00a036927079.","DOI":"10.1161\/CIRCRESAHA.122.321858"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Voigt N, Trausch A, Knaut M, et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:472\u201380. https:\/\/doi.org\/10.1161\/CIRCEP.110.954636; PMID:\u00a020657029.","DOI":"10.1161\/CIRCEP.110.954636"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Cheng TY, Chen YC, Li SJ, et al. Interleukin-33\/ST2 axis involvement in atrial remodeling and arrhythmogenesis. Transl Res 2024;268:1\u201312. https:\/\/doi.org\/10.1016\/j.trsl.2024.01.006; PMID:\u00a038244770.","DOI":"10.1016\/j.trsl.2024.01.006"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Sunggip C, Shimoda K, Oda S, et al. TRPC5-eNOS axis negatively regulates ATP-induced cardiomyocyte hypertrophy. Front Pharmacol 2018;9:523. https:\/\/doi.org\/10.3389\/fphar.2018.00523; PMID:\u00a029872396.","DOI":"10.3389\/fphar.2018.00523"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lou Q, Li L, Liu G, et al. Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation. J Cardiovasc Pharmacol Ther 2023;28:10742484231185252. https:\/\/doi.org\/10.1177\/10742484231185252; PMID:\u00a037403470.","DOI":"10.1177\/10742484231185252"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Chousou PA, Chattopadhyay R, Tsampasian V, et al. Electrocardiographic predictors of atrial fibrillation. Med Sci (Basel) 2023;11:30. https:\/\/doi.org\/10.3390\/medsci11020030; PMID:\u00a037092499.","DOI":"10.3390\/medsci11020030"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Narasimhan B, Wu L, Shah AN. Atrial fibrillation and stroke prevention: \u201cLOOP\u201ding back with electrocardiograms to assess the predictive values of the P waves. Am J Cardiol 2023;207:283\u20134. https:\/\/doi.org\/10.1016\/j.amjcard.2023.09.031; PMID:\u00a037769572.","DOI":"10.1016\/j.amjcard.2023.09.031"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Loghin C, Karimzadehnajar K, Ekeruo IA, et al. Outcome of pulmonary vein isolation ablation for paroxysmal atrial fibrillation: predictive role of left atrial mechanical dyssynchrony by speckle tracking echocardiography. J Interv Card Electrophysiol 2014;39:7\u201315. https:\/\/doi.org\/10.1007\/s10840-013-9841-3; PMID:\u00a024310816.","DOI":"10.1007\/s10840-013-9841-3"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Eichenlaub M, Mueller-Edenborn B, Minners J, et al. Left atrial hypertension, electrical conduction slowing, and mechanical dysfunction: the pathophysiological triad in atrial fibrillation-associated atrial cardiomyopathy. Front Physiol 2021;12:670527. https:\/\/doi.org\/10.3389\/fphys.2021.670527; PMID:\u00a034421634.","DOI":"10.3389\/fphys.2021.670527"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Deneke T, Kutyifa V, Hindricks G, et al. Pre- and post-procedural cardiac imaging (computed tomography and magnetic resonance imaging) in electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and European Association of Cardiovascular Imaging of the European Society of Cardiology. Europace 2024;26:euae108. https:\/\/doi.org\/10.1093\/europace\/euae108; PMID:\u00a038743765.","DOI":"10.1093\/europace\/euae166"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis. Eur Heart J 2020;41:1123\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehz786; PMID:\u00a031713590.","DOI":"10.1093\/eurheartj\/ehz786"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 2014;311:498\u2013506. https:\/\/doi.org\/10.1001\/jama.2014.3; PMID:\u00a024496537.","DOI":"10.1001\/jama.2014.3"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J 2013;34:2731\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/eht194; PMID:\u00a023761394.","DOI":"10.1093\/eurheartj\/eht194"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Ju W, Li M, Wang DW, et al. Idiopathic isolated fibrotic atrial cardiomyopathy underlies unexplained scar-related atrial tachycardia in younger patients. Europace 2018;20:1657\u201365. https:\/\/doi.org\/10.1093\/europace\/eux340; PMID:\u00a029293999.","DOI":"10.1093\/europace\/eux340"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Disertori M, Mas\u00e8 M, Marini M, et al. Electroanatomic mapping and late gadolinium enhancement MRI in a genetic model of arrhythmogenic atrial cardiomyopathy. J Cardiovasc Electrophysiol 2014;25:964\u201370. https:\/\/doi.org\/10.1111\/jce.12440; PMID:\u00a024758425.","DOI":"10.1111\/jce.12440"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Lip GYH, Martin DT. Alterations in atrial electrogram amplitude as steady sinus rhythm transitions to paroxysmal atrial fibrillation during continuous monitoring in patients with implantable cardiac devices: insights from the Impact study. J Cardiovasc Electrophysiol 2021;32:1357\u201363. https:\/\/doi.org\/10.1111\/jce.14997; PMID:\u00a033709486.","DOI":"10.1111\/jce.14997"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Kamel H, Longstreth WT Jr, Tirschwell DL, et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA 2024;331:573\u201381. https:\/\/doi.org\/10.1001\/jama.2023.27188; PMID:\u00a038324415.","DOI":"10.1001\/jama.2024.6855"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Kamel H, Elkind MS, Kronmal RA, et al. Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial. Eur Stroke J 2025;10:495\u2013501. https:\/\/doi.org\/10.1177\/23969873241276358; PMID:\u00a039212178.","DOI":"10.1177\/23969873241276358"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Wang W, Zhou T, Li J, et al. Association between NT-proBNP levels and risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Heart 2025;111:109\u201316. https:\/\/doi.org\/10.1136\/heartjnl-2024-324685; PMID:\u00a039643423.","DOI":"10.1136\/heartjnl-2024-324685"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Didier R, Garnier L, Duloquin G, et al. Distribution of atrial cardiomyopathy markers and association with atrial fibrillation detected after ischaemic stroke in the SAFAS study. Stroke Vasc Neurol 2024;9:165\u201373. https:\/\/doi.org\/10.1136\/svn-2023-002447; PMID:\u00a037429637.","DOI":"10.1136\/svn-2023-002447"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Fabritz L, Al-Taie C, Borof K, et al. Biomarker-based prediction of sinus rhythm in atrial fibrillation patients: the EAST-AFNET 4 biomolecule study. Eur Heart J 2024;45:5002\u201319. https:\/\/doi.org\/10.1093\/eurheartj\/ehae611; PMID:\u00a039215973.","DOI":"10.1093\/eurheartj\/ehae611"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Nattel S, Heijman J, Zhou L, Dobrev D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ Res 2020;127:51\u201372. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316363; PMID:\u00a032717172.","DOI":"10.1161\/CIRCRESAHA.120.316363"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954\u201368. https:\/\/doi.org\/10.1161\/01.cir.92.7.1954; PMID:\u00a07671380.","DOI":"10.1161\/01.CIR.92.7.1954"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Wijffels MC, Kirchhof CJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997;96:3710\u201320. https:\/\/doi.org\/10.1161\/01.cir.96.10.3710; PMID:\u00a09396475.","DOI":"10.1161\/01.CIR.96.10.3710"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87\u201395. https:\/\/doi.org\/10.1161\/01.cir.100.1.87; PMID:\u00a010393686.","DOI":"10.1161\/01.CIR.100.1.87"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Molina CE, Abu-Taha IH, Wang Q, et al. Profibrotic, electrical, and calcium-handling remodeling of the atria in heart failure patients with and without atrial fibrillation. Front Physiol 2018;9:1383. https:\/\/doi.org\/10.3389\/fphys.2018.01383; PMID:\u00a030356673.","DOI":"10.3389\/fphys.2018.01383"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Guichard JB, Xiong F, Qi XY, et al. Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. Cardiovasc Res 2021;117:462\u201371. https:\/\/doi.org\/10.1093\/cvr\/cvaa007; PMID:\u00a031977017.","DOI":"10.1093\/cvr\/cvaa007"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034646; PMID:\u00a029792299.","DOI":"10.1161\/CIRCULATIONAHA.118.034646"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297\u2013317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641; PMID:\u00a031504452.","DOI":"10.1093\/eurheartj\/ehz641"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Mehdizadeh M, Naud P, Abu-Taha IH, et al. The role of cellular senescence in profibrillatory atrial remodelling associated with cardiac pathology. Cardiovasc Res 2024;120:506\u201318. https:\/\/doi.org\/10.1093\/cvr\/cvae003; PMID:\u00a038181429.","DOI":"10.1093\/cvr\/cvae003"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Salman O, Zamani P, Zhao L, et al. Prognostic significance and biologic associations of senescence-associated secretory phenotype biomarkers in heart failure. J Am Heart Assoc 2024;13:e033675. https:\/\/doi.org\/10.1161\/JAHA.123.033675; PMID:\u00a039206715.","DOI":"10.1161\/JAHA.123.034295"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Howie JO, Dziano JK, Ariyaratnam JP, et al. The association of age and left atrial dysfunction in patients with atrial fibrillation. Heart Rhythm 2025;22:e1137\u201345. https:\/\/doi.org\/10.1016\/j.hrthm.2025.07.005; PMID:\u00a040651587.","DOI":"10.1016\/j.hrthm.2025.07.005"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Kadappu KK, Boyd A, Eshoo S, et al. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction? Eur Heart J Cardiovasc Imaging 2012;13:1016\u201323. https:\/\/doi.org\/10.1093\/ehjci\/jes084; PMID:\u00a022544873.","DOI":"10.1093\/ehjci\/jes084"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Liu Y, Wang K, Su D, et al. Noninvasive assessment of left atrial phasic function in patients with hypertension and diabetes using two-dimensional speckle tracking and volumetric parameters. Echocardiography 2014;31:727\u201335. https:\/\/doi.org\/10.1111\/echo.12492; PMID:\u00a024354465.","DOI":"10.1111\/echo.12492"},{"key":"ref82","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2022;79:390\u2013414. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.021; PMID:\u00a035086661."},{"key":"ref83","unstructured":"Writing Committee Members, Ommen SR, Ho CY, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. J Am Coll Cardiol 2024;83:2324\u2013405. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.014; PMID:\u00a038727647."},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Sivalokanathan S, Zghaib T, Greenland GV, et al. Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging. JACC Clin Electrophysiol 2019;5:364\u201375. https:\/\/doi.org\/10.1016\/j.jacep.2018.10.016; PMID:\u00a030898240.","DOI":"10.1016\/j.jacep.2018.10.016"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Niemel\u00e4 M, Uusitalo V, P\u00f6yh\u00f6nen P, et al. Incidence and predictors of atrial fibrillation in cardiac sarcoidosis: a multimodality imaging study. JACC Cardiovasc Imaging 2022;15:1622\u201331. https:\/\/doi.org\/10.1016\/j.jcmg.2022.02.025; PMID:\u00a036075623.","DOI":"10.1016\/j.jcmg.2022.02.025"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"M\u00fcller ML, Brand A, Mattig I, et al. Myocardial inflammation in cardiac transthyretin amyloidosis: prevalence and potential prognostic implications. Circ Heart Fail 2025;18:e012146. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012146; PMID:\u00a039866106.","DOI":"10.1161\/CIRCHEARTFAILURE.124.012146"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Nochioka K, Quarta CC, Claggett B, et al. Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2017;18:1128\u201337. https:\/\/doi.org\/10.1093\/ehjci\/jex097; PMID:\u00a028637305.","DOI":"10.1093\/ehjci\/jex097"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Leiva O, AbdelHameid D, Connors JM, et al. Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2021;3:619\u201334. https:\/\/doi.org\/10.1016\/j.jaccao.2021.08.011; PMID:\u00a034988471.","DOI":"10.1016\/j.jaccao.2021.08.011"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Navi BB, Elkind MSV, Zhang C, et al. History of cancer and atrial cardiopathy: a secondary analysis of the ARCADIA clinical trial. J Am Heart Assoc 2025;14:e040543. https:\/\/doi.org\/10.1161\/JAHA.124.040543; PMID:\u00a040265582.","DOI":"10.1161\/JAHA.124.040543"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2019422;PMID:\u00a032865375.","DOI":"10.1056\/NEJMoa2019422"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Gu Z, Guo L, Liu C, et al. Real-world evidence of early rhythm control in patients with atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2024;412:132327. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132327; PMID:\u00a038964555.","DOI":"10.1016\/j.ijcard.2024.132327"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Eckardt L, Sehner S, Suling A, et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J 2022;43:4127\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehac471; PMID:\u00a036036648.","DOI":"10.1093\/eurheartj\/ehac471"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Kantharia BK, Wehrens XHT, Linz D. Superior vena cava and atrial cardiomyopathy: role of adjunctive superior vena cava isolation ablation in atrial fibrillation. Europace 2025;27:euaf204. https:\/\/doi.org\/10.1093\/europace\/euaf204; PMID:\u00a040892980.","DOI":"10.1093\/europace\/euaf204"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Fujimoto H, Doi N, Okayama S, et al. Long-term prognosis of patients undergoing radio-frequency catheter ablation for atrial fibrillation: comparison between heart failure subtypes based on left ventricular ejection fraction. Europace 2022;24:576\u201386. https:\/\/doi.org\/10.1093\/europace\/euab201; PMID:\u00a034463733.","DOI":"10.1093\/europace\/euab201"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1707855; PMID:\u00a029385358.","DOI":"10.1056\/NEJMoa1707855"},{"key":"ref96","unstructured":"Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med 2023;389:1380\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2306037; PMID:\u00a037634135."},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Johner N, Namdar M, Shah DC. Safety, efficacy and prognostic benefit of atrial fibrillation ablation in heart failure with preserved ejection fraction. Arrhythm Electrophysiol Rev 2022;11:e18. https:\/\/doi.org\/10.15420\/aer.2022.10; PMID:\u00a036304203.","DOI":"10.15420\/aer.2022.10"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Linz D, Hermans A, Tieleman RG. Early atrial fibrillation detection and the transition to comprehensive management. Europace 2021;23(Suppl 2):ii46\u201351. https:\/\/doi.org\/10.1093\/europace\/euaa424; PMID:\u00a033837752.","DOI":"10.1093\/europace\/euaa424"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928; PMID:\u00a032222134.","DOI":"10.1056\/NEJMoa1915928"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the Victoria trial. Eur J Heart Fail 2021;23:1300\u201312. https:\/\/doi.org\/10.1002\/ejhf.2285; PMID:\u00a034191395.","DOI":"10.1002\/ejhf.2285"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Zhang R, Mesquita T, Cho JH, et al. Systemic delivery of extracellular vesicles attenuates atrial fibrillation in heart failure with preserved ejection fraction. JACC Clin Electrophysiol 2023;9:147\u201358. https:\/\/doi.org\/10.1016\/j.jacep.2022.09.012;PMID:\u00a036858679.","DOI":"10.1016\/j.jacep.2022.09.012"}],"container-title":["Arrhythmia &amp; Electrophysiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.53","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:40:31Z","timestamp":1773150031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerjournal.com\/articleindex\/aer.2025.53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":102,"URL":"https:\/\/doi.org\/10.15420\/aer.2025.53","relation":{},"ISSN":["2050-3369","2050-3377"],"issn-type":[{"value":"2050-3369","type":"print"},{"value":"2050-3377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"e11"}}